A Phase 2 proof-of-concept study of GB001 in chronic spontaneous urticaria
Latest Information Update: 19 Nov 2019
At a glance
- Drugs GB 001 (Primary)
- Indications Urticaria
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 12 Nov 2019 Planned initiation date changed from 1 Jul 2019 to 1 Jan 2020, according to a Gossamer Bio media release.
- 12 Nov 2019 According to a Gossamer Bio media release, the company plans to initiate this study in the first half of 2020.
- 21 May 2019 New trial record